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Angiogenesis is an important event both in the development of allergic inﬂammatory responses and in the pathophysiology of
tissue remodeling in allergic diseases. In the present study, therefore, we examined the inﬂuence of antihistamines on angiogenesis
through the choice of epinastine hydrochloride (EP) and murine mast cells in vitro. Mast cells (5×105 cells/mL) presensitized with
murine IgE speciﬁc for ovalbumin (OVA) were stimulated with 10ng/mL OVA in the presence of various concentrations of EP for
4 hours. The levels of angiogenesis factors, keratinocyte-derived chemokine (KC), tumor necrosis factor-α (TNF), and vascular
endothelial growth factor (VEGF) in culture supernatants, were examined by ELISA. We also examined mRNA expression for
the angiogenesis factors by RT-PCR. EP signiﬁcantly inhibited the production of KC, TNF, and VEGF induced by IgE-dependent
mechanism at more than 25ng/mL. Semiquantitative analysis using RT-PCR showed that EP also signiﬁcantly reduced mRNA
expressions for KC, TNF, and VEGF. These results strongly suggest that EP suppresses angiogenesis factor production through the
inhibition of mRNA expression in mast cells and results in favorable modiﬁcation of clinical conditions of allergic diseases.
Copyright © 2008 K. Asano et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Allergic rhinitis (AR) is well accepted to be a symptomatic
disease of the nasal mucosa caused by an IgE-mediated
allergic inﬂammation, and characterized by nasal itching,
sneezing, water rhinorrhea, and nasal obstruction, which
makes breathing through the nose diﬃcult [1]. These clinical
symptoms are also well known to be mediated by several
factors such as histamine, prostaglandins, and other inﬂam-
matory mediators (e.g., inﬂammatory cytokines) secreted
from activated inﬂammatory cells including eosinophils,
mast cells, and T cells in the local of inﬂammation [1].
In addition to these classical immune responses, structural
changes within the nasal walls have also been reported
in patients with allergic rhinitis. These structural changes
include epithelial disruption, mucus gland hypertrophy,
mucosalmyoﬁbroblasttransformation,andincreasedmatrix
protein deposition [2, 3]. These cellular changes are now
called tissue remodeling and two groups of proteins matrix
metalloproteinases (MMPs) and their counter-regulatory
inhibitors, TIMPs, are generally accepted to be important
factors for tissue remodeling [4].
Recently, there is increasing evidence that angiogenesis
plays an important role in both the development of inﬂam-
mation and in the pathophysiology of tissue remodeling
during allergic responses [2, 5, 6]. Numerous numbers of
inducers of angiogenesis have been identiﬁed, including
vascular endothelial growth factor (VEGF), angiogenin,
transforming growth factor (TGF), tumor necrosis factor-
α (TNF) and interleukin (IL)-8, and others [6, 7]. Some
experimental evidence strongly suggests that in inﬂam-
mation, inﬁltrating inﬂammatory cells and some resident
cells are the producers of the angiogenic factors. Human
neutrophils [8]a n dT - l y m p h o c y t e s[ 9] synthesize and secret
the angiogenic factors such as VEGF and IL-8. Peripheral
blood eosinophils were found to secrete the factors when
stimulated with granulocyte-macrophage colony stimulating
factor and IL-5 in vitro [10]. Fibroblasts, as resident cells,
are also a demonstrated rich source of the angiogenic factors
[11]. Among these cells, mast cells and eosinophils have2 Mediators of Inﬂammation
been highlighted as the eﬀector cells in angiogenesis during
allergic inﬂammation [7, 12]. Although recent researches
have focused on the ability of antihistamines, which are the
most important agent in the treatment of allergic diseases
including AR, to modulate the release of inﬂammatory
cytokines from mast cells and eosinophils, there is little
information regarding the eﬀects of antihistamines on
angiogenesis. The present study, therefore, was undertaken
to examine the inﬂuence of epinastine hydrochloride (EP),
the most famous antihistamine in Japan, on keratinocyte-
derived chemokine (KC), TNF, and VEGF that are known to
be major factors aﬀecting angiogenesis [13] in murine mast
cells in IgE-dependent manner.
2. MATERIALS AND METHODS
2.1. Mice
Speciﬁc pathogen-free BALB/c male mice were purchased
from Charles River Japan Inc. (Atsugi, Japan).
2.2. Agents
EP was kindly donated by Nihon Boehringer Ingelheim Co.
Ltd. (Tokyo, Japan) as a preservative-free pure powder. This
was dissolved in RPMI-1640 medium (SIGMA-ALDRICH
Inc., St Louis, MO, USA) supplemented with 10% heat inac-
tivatedfetalcalfserumfromGIBCOBRL(Gaithersburg,Md,
USA; RPMI-FCS) at a concentration of 10mg/mL, sterilized
bypassingthrough0.2μmﬁlterandthendilutedwithRPMI-
FCS at appropriate concentrations for experiments.
2.3. PreparationofmouseIgE
BALB/c mice were injected intraperitoneally twice with a 2-
week interval with 5.0mg of ovalbumin from WAKO Pure
Chemicals (OVA; Osaka, Japan) absorbed with 0.5mg of
alum in a volume of 0.5mL. After one week, blood was
obtained by cardiac puncture and OVA speciﬁc IgE was
puriﬁed with KAPTIV-AE from Tecnogen S.C.p.A. (Monte
Verna, Italy) according to the manufacturer’s instructions.
The protein concentration of the extracted solution was
measured with protein assay kit from Bio-Rad Laboratories
(Hercules, Calif, USA) and adjusted to 1.0mg/mL with
RPMI-FCS.
2.4. Preparationofmastcells
Mouse peritoneal mast cells were isolated as previously
described [13]. Brieﬂy, mice were anesthetized with diethyl
ether and exanguinated by decapitation. The peritoneal
cavity was rinsed with 10mL of heparinized (10IU/mL)
calcium and magnesium-free Hank’s solution (HBSS). The
ﬂuid was collected, centrifuged at 150g for 15 minutes at
4◦C. The pelleted cells were resuspended in HBSS containing
0.1% bovine serum albumin and submitted to a continuous
isotonic Percoll gradient (72%) for mast cell isolation.
Puriﬁed mast cells were resuspended in RPMI-FCS. The cell
purity (>96%) and viability (>98%) were evaluated by alcian
blue and trypan blue exclusion staining, respectively.
2.5. Sensitizationandtreatmentofmastcells
To sensitize mast cells with IgE, 1 ×106, cells were incubated
with 500ng/mL of OVA-speciﬁc IgE for 30 minutes at 37◦C,
washed, and resuspended in RPMI-FCS. The sensitized mast
cells (5 × 105 cells/mL) were stimulated with 10ng/mL OVA
for 4 hours in the presence of various concentrations of EP
in a total volume of 2.0mL. The culture supernatants were
collected after centrifugation of cell suspension at 150g for
1 5m i n u t e sa t4 ◦Ca n ds t o r e da t−40◦C prior to assay for
factors. To obtain water-soluble intracellular contents, the
pelleted cells suspended in 2.0mL HBSS were then sonically
disrupted in an ice cold water bath for 5 minutes and
centrifugedat3000gfor30minutesat4◦C.Thesupernatants
were obtained and stored at −40◦C until used. In cases of
examining mRNA expression, mast cells sensitized IgE were
stimulated with OVA in a similar manner for 4 hours and
stored at −80◦C until used. In all experiments, EP was added
tocellculturesonehourbeforestartingantigenicstimulation
and cells were cultured in triplicate.
2.6. Assayforfactors
KC, TNF, and VEGF levels in culture supernatants were
assayed using commercially available mouse ELISA test kits
(R & D systems, Minneapolis, Minn, USA) according to
manufacturer’s recommendation.
2.7. Real-timepolymerasechainreaction
mRNA was extracted from mast cells using μMACS mRNA
isolation kits from Miltenyi Biotec GmbH (Bergisch
Gladbach, Germany) according to the manufacturer’s
instructions. The ﬁrst-strand complementary DNA (cDNA)
synthesis from 1.0μg mRNA was performed using the
SuperScript Preampliﬁcation System for cDNA synthesis
from GIBCO BRL (Gaithersburg, Md, USA). PCR was then
carried out using a GeneAmp 5700 Sequence Detection
System from Applied Biosystems (Foster City, Calif, USA).
PCR mixture consisted of 2.0μl of sample cDNA solution
(10.0ng/mL), 25.0μl of SYBR-Green Mastermix (Applied
Biosystems), 0.3μl of both sense and antisense primers, and
distilled water to give a ﬁnal volume of 50.0μl. The reaction
was conducted as follows: 4 minutes at 95◦C, followed by 40
cycles of 15 seconds at 95◦C, and 60 seconds at 60◦C. β-actin
was ampliﬁed as an internal control. mRNA levels were
calculated by using the comparative parameter threshold
cycle (Ct) and normalized to β-actin. Oligonucleotide
sequences of the primers used are as follows: for KC
[14], 5 -GCGCCTATCGCCAATGAG-3  (sense) and 5 -
AGGGCAACACCTTCAAGCTCT-3  (antisense); for VEGF
[15], 5 -CAGCTATTGCCGTCCGATTGAGA-3  (sense)
and 5 -TGCTGGCTTTGGGAGGTTTGAT- 3  (antisense);
for TNF [16], 5 -CCTGTAGCCCACGTCGTAGC-3  and
5 -TTGACCTCAGCGCTGAGTTG-3 ;f o rβ-actin [16],
5 -ACCCACACTTGTGCCCATCTA-3  (sense) and 5 -
CGGAACCGCTCATTGCC-3  (antisense).K. Asano et al. 3
2.8. Statisticalanalysis
The statistical signiﬁcance of the data between the control
and experimental groups was analyzed by ANOVA followed
by Fisher’s PLSD test. P<. 05 was considered statistically.
3. RESULTS
3.1. SuppressiveactivityofEPonKC,TNF,andVEGF
productionfrommastcells
The ﬁrst set of experiments was undertaken to examine
the inﬂuence of EP on KC, TNF and VEGF production
from mast cells induced by antigenic stimulation in vitro.
Mast cells (5 × 105 cells/mL) sensitized with OVA speciﬁc
IgE were stimulated with OVA in the presence of 0, 10,
20, 25, 30, and 40ng/mL EP for 4 hours. Factor levels
in culture supernatants were assayed by ELISA. As shown
in Figures 1(a) and 1(b), treatment of cells with EP at
quantitieslowerthan20ng/mLdidnotcausethesuppression
of the release of both KC and TNF, which was increased by
antigenic stimulation. However, EP signiﬁcantly suppressed
the ability of cells to release both KC and TNF after antigenic
stimulation, when the agent was added to cell cultures at
25ng/mL and higher (Figures 1(a) and 1(b)). The data in
Figure 1(c)alsoshowedthesuppressiveeﬀectofEPonVEGF
release from mast cells induced by antigenic stimulation;
treatment of mast cells with EP at more than 30ng/mL
signiﬁcantly suppressed increase in VEGF levels induced by
antigenic stimulation. We then examined factor levels in
water-soluble intracellular extracts by ELISA. As shown in
Figures 2(a), 2(b),a n d2(c), treatment of mast cells with
EP did not cause the prevention of factor release from cells;
the levels of factors (KC, TNF, and VEGF) in extracts from
cells treated with EP at 40ng/mL are nearly identical (not
signiﬁcant) to that in stimulated but nontreated control
(OVA + IgE).
3.2. InhibitoryeffectsofEPonthemRNAexpression
forKC,TNF,andVEGF
The second group of experiments were undertaken to
examine the inﬂuence of EP on mRNA expression for
KC, TNF, and VEGF after OVA stimulation. Mast cells
(5 × 105 cells/mL) sensitized with OVA speciﬁc IgE were
stimulated with OVA in the presence of 0, 10, 20, 25, 30, and
40ng/mL EP for 4 hours. mRNA expression was examined
by semiquantitative RT-PCR. As shown in Figures 3(a), 3(b),
and 3(c), treatment of mast cells with EP suppressed mRNA
expression for factors examined, which was increased by
OVA stimulation. The minimum concentration of the agent,
which caused signiﬁcant suppression, was 25 to 30ng/mL.
4. DISCUSSION
EP is a selective and potent H1-receptor antagonist with no
anticholinergic and sedative eﬀect [17, 18]. Our previous
work clearly showed that EP could suppress thymus and
activation-regulated chemokine (TARC) production from
human peripheral blood T cells induced by IL-4 and cos-
timulatory molecule stimulation [19]. It is also observed that
EP could antagonize against IL-4-mediated T cell cytokine
imbalance in vitro [20]. These reports strongly suggest that
the modulation of EP on both cytokine and chemokine
production, which are responsible for the development of
allergic immune responses, consists, in part, of a therapeutic
mode of action of the agent on allergic diseases.
The structural changes in the airway walls including
epithelium, submucosa, smooth muscle, and vasculature are
referred to as airway remodeling, which is mainly induced
by several types of MMPs, in allergic diseases such as
asthma and allergic rhinitis [4, 21, 22]. Furthermore, there
is accumulated evidence that allergic inﬂammation causes
structuralchangesinthenasalwall,whichischaracterizedby
angiogenesis and subepithelial basement membrane hyper-
trophy[2,3,23,24].Angiogenesisinvolvesdestructionofthe
basement membrane by MMPs, migration and proliferation
of endothelial cells, and transformation of endothelial cells
to form tubes [25]. This process is mediated by numerous
inducers, including members of ﬁbroblast growth factor
family, VEGF, angiogenin, transforming growth factor, TNF,
interleukins and chemokines [7, 26]. Among them, VEGF
is the most potent regulator of angiogenesis and induces
the enhancement of proliferation, migration, and tube
formation of endothelial cells [7, 26]. VEGF promotes
secretion of MMP-1 and the expression of chemokines,
as well as intracellular adhesion molecule and E-selectin
[7]. VEGF also causes vasodilation, which is responsible
for edema, inﬂammatory cell inﬁltration and increase in
nasal secretions, through the induction of the endothelial
nitric oxide synthase and the subsequent increase in nitric
oxide production [7, 26]. Furthermore, VEGF stimulates
monocyte chemotaxis and contributes to the recruitment of
bone-marrow-derived endothelial cells in angiogenesis [7].
Together with the present results, showing the suppressive
activity of EP on VEGF production may be interpreted as
meaning that some of therapeutic eﬀects of EP in AR depend
on its suppression of VEGF production from mast cells. In
addition to VEGF, TNF is considered to be a multifunctional
proinﬂammatory cytokine that plays a central role in the
initiation and maintenance of many inﬂammatory diseases,
including asthma and allergic rhinitis. Although TNF is
associated predominantly with Th1-dependent inﬂamma-
tion, recent reports indicate that TNF is essential for the
production of the Th2 type cytokines and for inﬁltration of
Th2 T cells into the site of allergic inﬂammation [27]. TNF is
produced by a variety of inﬂammatory cells, especially mast
cells and macrophages through IgE-dependent mechanisms
and also enhanced the eﬀect of both IL-4 and IL-10 on
antigen-speciﬁc IgE production [27, 28]. Furthermore, TNF
increased the expression of mRNA for endothelial-leukocyte
adhesion molecule-1 (ELAM-1) and vascular cell adhesion
molecule-1 (VCAM-1), which are essential for eosinophil
migration into allergic inﬂammatory site, in nasal mucosa
after ovalbumin sensitization in mice [27], suggesting that
inhibition of TNF production from mast cells through IgE-
dependent mechanisms may also partially account for the
therapeutic mechanisms of the agent on allergic diseases.4 Mediators of Inﬂammation
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Figure 1: Suppressive activity of epinastine hydrochloride (EP) on angiogenic factor production from mast cells in IgE-dependent
mechanism. Murineperitoneal mastcells (5×105 cells/mL) sensitized with IgE speciﬁc for ovalbumin (OVA) were stimulated with 10ng/mL
OVA in the presence of various concentrations of EP for 4 hours. The levels of angiogenic factors in culture supernatants were analyzed by
ELISA. The data were expressed as the mean pg/mL ± SE of triplicate cultures. KC: keratinocyte-derived chemokine (a); TNF: TNF-α (b);
VEGF: vascular endothelial growth factor (c); ∗P<. 05 versus control (EP at 0ng/mL).
KC (murine homolog of IL-8), a member of CXC
subfamily, is produced by several types of immune cells,
including epithelial cells, macrophages, mast cells, and lym-
phocytes after immunological and nonimmunological stim-
ulation [29]. Although several reports clearly showed that
the presence of large amount of IL-8, chemoattractants for
neutrophils and eosinophils, in nasal lavage ﬂuid obtained
from allergic rhinitis [30–32], the role of this chemokine is
limited in granulocyte inﬁltration into inﬂammatory sites
of allergic rhinitis [29]. On the other hand, addition of
IL-8 into human microvascular endothelial cells cultured
on the surface of a three-dimensional collagen gel-caused-
tube-like structure formation [32]. It is also reported that
administration of anti-IL-8 into rabbit corneas signiﬁcantlyK. Asano et al. 5
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Figure 2: Inﬂuence of epinastine hydrochloride (EP) on angiogenic factor release from mast cells in IgE-dependent mechanism. Murine
peritoneal mast cells (5×105 cells/mL) sensitized with IgE speciﬁc for ovalbumin (OVA) were stimulated with 10ng/mL OVA. After 4 hours,
cells were collected, sonically disrupted, and the levels of angiogenic factors in cytosole were examined by ELISA. The data are expressed as
the mean pg/mL ± SE of triplicate cultures. KC: keratinocyte-derived chemokine (a); TNF: TNF-α (b); VEGF: vascular endothelial growth
factor (c); ∗P<. 05 versus control (EP at 0ng/mL).
inhibits newly vessel formation (angiogenesis) induced by
implantation with ethylene vinyl acetate pellets containing
TNF [33], indicating that IL-8 plays an essential role in TNF-
mediated angiogenesis. From these reports, the inhibitory
action of EP on KC production from mast cells by IgE-
dependentmechanismsmayalsohaveimportanttherapeutic
implications for allergic diseases.
Although the present results clearly show the inhibitory
actionofEPontheproductionofproangiogenicfactorsfrom
mast cells by antigenic stimulation through the suppression
of mRNA expression, the precise mechanisms by which EP
could inhibit the production of proangiogenic factors from
mast cells are not clear at present. The major stimulus for
mast cell activation is the aggregation of the high aﬃnity
receptor for IgE so-called FcεRI [34]. Crosslinking of FcεRI-
bound IgE-molecules with speciﬁc allergen activates the
receptor-associated tyrosine kinases and the initiation of
further phosphorylation of downstream molecules such as6 Mediators of Inﬂammation
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Figure 3: Suppressive activity of epinastine hydrochrolide (EP) on mRNA expression for angiogenic factors in mast cells in IgE-mediated
mechanism. Murineperitoneal mastcells (5×105 cells/mL) sensitized with IgE speciﬁc for ovalbumin (OVA) were stimulated with 10ng/mL
OVA for 4 hours. mRNA expression for angiogenic factors was examined by real-time RT-PCR. The data are expressed as the mean ± SE of
triplicate cultures. KC: keratinocyte-derived chemokine (a); TNF: TNF-α (b); VEGF: vascular endothelial growth factor (c); ∗P<. 05 versus
control (EP at 0ng/mL).
Syk, phosphatidyl-inositol-3-OH-kinase, and phospholipase
Cγ [34]. These proximal signaling events activate protein
kinase C that ultimately initiates mast cell eﬀector functions
such as degranulation and cytokine production [34]. The
activation of these kinases is also reported to require Ca2+,
which is increased by crosslinking of IgE with allergen on
mast cell surface [35]. It has been reported that EP at more
than 10
−5 M could inhibit Ca2+ inﬂux and Ca2+ release
from the intracellular calcium store of mast cells exposed
to compound 48/80 and substance P [36, 37]. Judging from
these reports, it is strongly suggested that EP inhibits the
changes in Ca2+ concentration in cytosole induced by anti-
genic stimulation and results in suppression of angiogenic
factor production from mast cells. In addition to these
signaling pathways, transcription factor NF-κB regulates the
expression of inﬂammatory gene products in many diﬀerentK. Asano et al. 7
cell lineages. In mast cells, the expression of TNF, IL-6,
and IL-8 gene after FcεRI ligation strictly depends on the
activation of NF-κB[ 34, 35]. NF-κB is a ubiquitous protein
transcription factor and normally resides in an inactive state
in cytoplasm. However, when activated it translocates to the
nucleus, binds the DNA, and activates genes. Activation of
NF-κB is induced by degradation and dissociation of IκB,
an endogenous inhibitor of NF-κB, through Ca2+-dependent
and -independent mechanisms [20]. Together with the
presentresults,thereisalsopossibilitythatEPinhibitsNF-κB
activation through Ca-independent mechanisms and results
in suppression of angiogenic factor production from mast
cells.
Pharmacological studies have revealed that, after oral
administration of EP into patients with allergic diseases at a
single dose of 20mg, plasma concentration of this agent was
gradually increased and attains a plateau at 26.9 ±9.1ng/mL
[38], suggesting thatthe ﬁndings ofthe present in vitrostudy
may reﬂect the biological function of EP in vivo.
In conclusion, the present results demonstrate that the
inhibitory action of EP on angiogenic factor production
consists, in part, of a therapeutic mode of action of the agent
on allergic diseases, including atopic allergy and pollinosis.
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